The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
The mutational landscape of lethal castration-resistant prostate cancer
Open accessAbstract
Characterization of the prostate cancer transcriptome and genome has identified chromosomal rearrangements and copy number gains and losses, including ETS gene family fusions, PTEN loss and androgen receptor (AR) amplification, which drive prostate cancer development and progression to lethal, metastatic castration-resistant prostate cancer (CRPC). However, less is known about the role of mutations. Here we sequenced the exomes of 50 lethal, heavily pre-treated metastatic CRPCs obtained at rapid autopsy (including three different foci from the same patient) and 11 treatment-naive, high-grade localized prostate cancers. We identified low overall mutation rates even in heavily treated CRPCs (2.00 per megabase) and confirmed the monoclonal origin of lethal CRPC. Integrating exome copy number analysis identified disruptions of CHD1 that define a subtype of ETS gene family fusion-negative prostate cancer. Similarly, we demonstrate that ETS2, which is deleted in approximately one-third of CRPCs (commonly through TMPRSS2:ERG fusions), is also deregulated through mutation. Furthermore, we identified recurrent mutations in multiple chromatin- and histone-modifying genes, including MLL2 (mutated in 8.6% of prostate cancers), and demonstrate interaction of the MLL complex with the AR, which is required for AR-mediated signalling. We also identified novel recurrent mutations in the AR collaborating factor FOXA1, which is mutated in 5 of 147 (3.4%) prostate cancers (both untreated localized prostate cancer and CRPC), and showed that mutated FOXA1 represses androgen signalling and increases tumour growth. Proteins that physically interact with the AR, such as the ERG gene fusion product, FOXA1, MLL2, UTX (also known as KDM6A) and ASXL1 were found to be mutated in CRPC. In summary, we describe the mutational landscape of a heavily treated metastatic cancer, identify novel mechanisms of AR signalling deregulated in prostate cancer, and prioritize candidates for future study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We and other groups have identified tumor alterations that reactivate AR signaling during treatment with an ARSI2,22–29.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These mechanisms of resistance include AR gene amplification22,23, AR enhancer amplification2,24,25, AR mutation26, AR genomic structural rearrangements27, AR splice variants28 and polymorphisms in androgen metabolism genes29.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N. D., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E. G., Reva, B. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,713
The genomic complexity of primary human prostate cancer
Berger, M. F., Lawrence, M. S., Demichelis, F., Drier, Y., Cibulskis, K., Sivachenko, A., Sboner, A., Esgueva, R., Pflueger, D., Sougnez, C. L., et al. (2011) · Nature · doi:10.1038/nature09744 · Cited by 1,232
Diverse somatic mutation patterns and pathway alterations in human cancers
Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., Yue, P., Haverty, P. M., Bourgon, R., Zheng, J., et al. (2010) · Nature · doi:10.1038/nature09208 · Cited by 1,046
Molecular genetics of prostate cancer: new prospects for old challengesPreprint
Shen, M. M., & Abate-Shen, C. T. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 991
FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription
Lupien, M., Eeckhoute, J., Meyer, C. A., Wang, Q., Zhang, Y., Li, W., Carroll, J. S., Liu, X. S., & Brown, M. (2008) · Cell · doi:10.1016/j.cell.2008.01.018 · Cited by 983
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.056 · Cited by 897
Self-citationYu, J., Yu, J., Mani, R.-S., Cao, Q., Brenner, C. J., Cao, X., Wang, X., Wu, L., Li, J., Hu, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.018 · Cited by 850
Self-citationWang, Q., Li, W., Liu, X. S., Carroll, J. S., Jänne, O. A., Keeton, E. K., Chinnaiyan, A. M., Pienta, K. J., & Brown, M. A. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.041 · Cited by 689
Self-citationGenome-wide analysis of ETS-family DNA-binding in vitro and in vivo
Wei, G., Badis, G., Berger, M. F., Kivioja, T., Palin, K., Enge, M., Bonke, M., Jolma, A., Varjosalo, M., Gehrke, A. R., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.106 · Cited by 568
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,005
Inflammation-Induced Tumorigenesis and Metastasis
Hibino, S., Kawazoe, T., Kasahara, H., Itoh, S., Ishimoto, T., Sakata‐Yanagimoto, M., & Taniguchi, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115421 · Cited by 319
Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome
Fabbri, G., Khiabanian, H., Holmes, A. B., Wang, J., Messina, M., Mullighan, C. G., Pasqualucci, L., Rabadán, R., & Dalla‐Favera, R. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20131448 · Cited by 307
Histone H3 lysine 4 methyltransferase KMT2D
Froimchuk, E., Jang, Y., & Ge, K. (2017) · Gene · doi:10.1016/j.gene.2017.06.056 · Cited by 307
Targeting DNA damage response in cancer therapy
Hosoya, N., & Miyagawa, K. (2014) · Cancer Science · doi:10.1111/cas.12366 · Cited by 309
Li, L., Karanika, S., Yang, G., Wang, J., Park, S., Broom, B. M., Manyam, G. C., Wu, W., Luo, Y., Basourakos, S. P., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aam7479 · Cited by 297
An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer
Chen, M., Zhang, J., Sampieri, K., Clohessy, J. G., Mendez, L., González‐Billalabeitia, E., Liu, X., Lee, Y.-R., Fung, J., Katon, J. M., et al. (2018) · Nature Genetics · doi:10.1038/s41588-017-0027-2 · Cited by 297
Wang, L., Xiong, H., Wu, F., Zhang, Y., Wang, J., Zhao, L., Guo, X., Chang, L.-J., Zhang, Y., You, M. J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.053 · Cited by 299
Karantanos, T., Evans, C. P., TOMBAL, B. F., Thompson, T. C., Montironi, R., & Isaacs, W. B. (2014) · European Urology · doi:10.1016/j.eururo.2014.09.049 · Cited by 292
Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer
Parolia, A., Cieslik, M., Chu, S.-C., Xiao, L., Ouchi, T., Zhang, Y., Wang, X., Vats, P., Cao, X., Pitchiaya, S., et al. (2019) · Nature · doi:10.1038/s41586-019-1347-4 · Cited by 284
Self-citationChen, Y., Chi, P., Rockowitz, S., Iaquinta, P. J., Shamu, T., Shukla, S., Gao, D., Sirota, I., Carver, B. S., Wongvipat, J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3216 · Cited by 289
The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer
Akamatsu, S., Wyatt, A. W., Lin, D., Lysakowski, S., Zhang, F., Kim, S., Tse, C., Wang, K., Mo, F., Haegert, A. M., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.012 · Cited by 281
Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches
Dietlein, F., Thelen, L., & Reinhardt, H. C. (2014) · Trends in Genetics · doi:10.1016/j.tig.2014.06.003 · Cited by 290
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
He, Y., Xu, W., Xiao, Y., Huang, H., Gu, D., & Ren, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01042-7 · Cited by 287
The oncogene ERG: a key factor in prostate cancer
Adamo, P., & Ladomery, M. (2015) · Oncogene · doi:10.1038/onc.2015.109 · Cited by 286
Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs
Alabi, S. B., & Crews, C. M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100647 · Cited by 279
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications
Aurilio, G., Cimadamore, A., Roberta Mazzucchelli, A., Antonio Lopez-beltran, B., Verri, E., Scarpelli, M., Massari, F., Liang Cheng, C., Santoni, M., & Montironi, R. (2020) · Cells · doi:10.3390/cells9122653 · Cited by 283
FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes
Adams, E., Karthaus, W. R., Hoover, E., Liu, D., Gruet, A., Zhang, Z., Cho, H., DiLoreto, R., Chhangawala, S., Liu, Y., et al. (2019) · Nature · doi:10.1038/s41586-019-1318-9 · Cited by 268
TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer
Groner, A. C., Cato, L., de Tribolet-Hardy, J., Bernasocchi, T., Janoušková, H., Melchers, D., Houtman, R., Cato, A. C. B., Tschopp, P., Gu, L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.012 · Cited by 274
Prensner, J. R., Zhao, S. G., Erho, N., Schipper, M. J., Iyer, M. K., Dhanasekaran, S. M., Magi‐Galluzzi, C., Mehra, R., Sahu, A., Siddiqui, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71113-1 · Cited by 263
Self-citationIntratumor DNA Methylation Heterogeneity Reflects Clonal Evolution in Aggressive Prostate Cancer
Brocks, D., Assenov, Y., Minner, S. J. P., Bogatyrova, O., Simon, R., Koop, C., Oakes, C. C., Zucknick, M., Lipka, D. B., Weischenfeldt, J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.053 · Cited by 268
Cheng, H. H., Pritchard, C. C., Boyd, T. E., Nelson, P. S., & Montgomery, B. (2015) · European Urology · doi:10.1016/j.eururo.2015.11.022 · Cited by 266
An, J., Wang, C., Deng, Y., Yu, L., & Huang, H. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.01.013 · Cited by 268
Long Noncoding RNAs in Cancer: From Function to Translation
Sahu, A., Singhal, U., & Chinnaiyan, A. M. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.08.010 · Cited by 262
Self-citationRecent Advances in Prostate Cancer Treatment and Drug Discovery
Nevedomskaya, E., Baumgart, S. J., & Haendler, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051359 · Cited by 262
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
Pagliarini, R. A., Shao, W., & Sellers, W. R. (2015) · EMBO Reports · doi:10.15252/embr.201439949 · Cited by 264
Schweizer, M. T., Antonarakis, E. S., Wang, H., Ajiboye, A. S., Spitz, A. N., Cao, H., Luo, J., Haffner, M. C., Yegnasubramanian, S., Carducci, M. A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010563 · Cited by 259
Cancer evolution: Darwin and beyond
Vendramin, R., Litchfield, K., & Swanton, C. (2021) · The EMBO Journal · doi:10.15252/embj.2021108389 · Cited by 269
TET proteins and the control of cytosine demethylation in cancer
Scourzic, L., Mouly, E., & Bernard, O. (2015) · Genome Medicine · doi:10.1186/s13073-015-0134-6 · Cited by 263
Pioneer factors as master regulators of the epigenome and cell fate
Balsalobre, A., & Drouin, J. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00464-z · Cited by 251
Mosquera, J. M., Beltran, H., Park, K., MacDonald, T. Y., Robinson, B. D., Tagawa, S. T., Perner, S., Bismar, T. A., Erbersdobler, A., Dhir, R., et al. (2013) · Neoplasia · doi:10.1593/neo.121550 · Cited by 247
Geng, C., He, B., Xu, L., Barbieri, C. E., Eedunuri, V. K., Chew, S. A., Zimmermann, M., Bond, R., Shou, J., Li, C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304502110 · Cited by 243
DNA Repair in Prostate Cancer: Biology and Clinical Implications
Mateo, J., Boysen, G., Barbieri, C. E., Bryant, H. E., Castro, E., Nelson, P., Olmos, D., Pritchard, C. C., Rubin, M. A., & Bono, J. S. D. (2016) · European Urology · doi:10.1016/j.eururo.2016.08.037 · Cited by 247
Su, W., Han, H. H., Wang, Y., Zhang, B., Zhou, B., Cheng, Y., Rumandla, A., Gurrapu, S., Chakraborty, G., Su, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.06.009 · Cited by 248
Survival Outcomes in Cancer Patients Predicted by a Partial EMT Gene Expression Scoring Metric
George, J. T., Jolly, M. K., Xu, S., Somarelli, J. A., & Levine, H. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3521 · Cited by 246
Pioneer transcription factors shape the epigenetic landscape
Mayran, A., & Drouin, J. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.r117.001232 · Cited by 249
The Mutational Landscape of Prostate Cancer
Barbieri, C. E., Bangma, C. H., Bjartell, A. S., Catto, J. W. F., Čulig, Z., Grönberg, H., Luo, J., Visakorpi, T., & Rubin, M. A. (2013) · European Urology · doi:10.1016/j.eururo.2013.05.029 · Cited by 244
Prostate carcinogenesis: inflammatory storms
Bono, J. S. D., Guo, C. W., Gürel, B., Marzo, A. M. D., Sfanos, K. S., Mani, R. S., Gil, J., Drake, C. G., & Alimonti, A. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0267-9 · Cited by 240
Biology and evolution of poorly differentiated neuroendocrine tumors
Rickman, D. S., Beltran, H., Demichelis, F., & Rubin, M. A. (2017) · Nature Medicine · doi:10.1038/nm.4341 · Cited by 230
IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling
Sheng, X., Nenseth, H. Z., Qu, S., Kuzu, O. F., Frahnow, T., Simon, L. M., Greene, S., Zeng, Q., Fazli, L., Rennie, P. S., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08152-3 · Cited by 235
Wei, L., Wang, J., Lampert, E. J., Schlanger, S. E., DePriest, A. D., Hu, Q., Gomez, E. C., Murakam, M., Glenn, S. T., Conroy, J. M., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.07.008 · Cited by 226
LSD1 activates a lethal prostate cancer gene network independently of its demethylase function
Sehrawat, A., Gao, L., Wang, Y., Bankhead, A., McWeeney, S. K., King, C. J., Schwartzman, J. A., Urrutia, J. A., Bisson, W. H., Coleman, D. J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1719168115 · Cited by 226
Hovelson, D. H., McDaniel, A. S., Cani, A. K., Johnson, B., Rhodes, K., Williams, P. D., Bandla, S., Bien, G., Choppa, P., Hyland, F., et al. (2015) · Neoplasia · doi:10.1016/j.neo.2015.03.004 · Cited by 224
Self-citationZhang, D., Park, D., Zhong, Y., Lu, Y., Rycaj, K., Gong, S., Chen, X., Liu, X., Chao, H., Whitney, P., et al. (2016) · Nature Communications · doi:10.1038/ncomms10798 · Cited by 225
Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets
CAMCAP Study Group, Wedge, D. C., Gundem, G., Mitchell, T., Woodcock, D. J., Martincorena, I., Ghori, M., Zamora, J., Butler, A. P., Whitaker, H. C., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0086-z · Cited by 227
Metabolic reprogramming in prostate cancer
Ahmad, F., Cherukuri, M. K., & Choyke, P. L. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01435-5 · Cited by 238
Raphael, B. J., Dobson, J. R., Oesper, L., & Vandin, F. (2014) · Genome Medicine · doi:10.1186/gm524 · Cited by 226
Self-citationPhosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer
Drake, J. M., Paull, E., Graham, N. A., Lee, J. K., Smith, B. A., Titz, B., Stoyanova, T. I., Faltermeier, C. M., Uzunangelov, V., Carlin, D. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.07.007 · Cited by 223
JAK-STAT signaling in cancer: From cytokines to non-coding genome
Pěnčík, J., Pham, H. T. T., Schmoellerl, J., Javaheri, T., Schlederer, M., Čulig, Z., Merkel, O., Moriggl, R., Grebien, F., & Kenner, L. (2016) · Cytokine · doi:10.1016/j.cyto.2016.06.017 · Cited by 221
CHD1 Is a 5q21 Tumor Suppressor Required for ERG Rearrangement in Prostate Cancer
Burkhardt, L., Fuchs, S., Krohn, A., Masser, S., Mäder, M., Kluth, M., Bachmann, F., Huland, H., Steuber, T. P., Graefen, M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1342 · Cited by 218
mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer
Zabala‐Letona, A., Arruabarrena-Aristorena, A., Martín-Martín, N., Fernández‐Ruiz, S., Sutherland, J. D., Clasquin, M. F., Tomás‐Cortázar, J., Jimenez, J., de Torres, I. M., Quang, P., et al. (2017) · Nature · doi:10.1038/nature22964 · Cited by 217
The complexity of prostate cancer: genomic alterations and heterogeneity
Boyd, L. K., Mao, X., & Lu, Y. (2012) · Nature Reviews Urology · doi:10.1038/nrurol.2012.185 · Cited by 216
Zhang, Y., Zheng, D., Zhou, T., Song, H., Hulsurkar, M. M., Su, N., Liu, Y., Wang, Z., Shao, L., Ittmann, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06177-2 · Cited by 219
Dong, Y., Yu, T., Ding, L., Laurini, E., Huang, Y., Zhang, M., Weng, Y., Lin, S., Chen, P., Marson, D., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b10021 · Cited by 221
Epigenetic modulations and lineage plasticity in advanced prostate cancer
Ge, R., Wang, Z., Montironi, R., Jiang, Z., Cheng, M., Santoni, M., Huang, K., Massari, F., Lü, X., Cimadamore, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.002 · Cited by 215
Seminal plasma as a diagnostic fluid for male reproductive system disorders
Drabovich, A. P., Saraon, P., Jarvi, K. A., & Diamandis, E. P. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.74 · Cited by 221
Targeting the MLL complex in castration-resistant prostate cancer
Malik, R., Khan, A. P., Asangani, I. A., Cieslik, M. P., Prensner, J. R., Wang, X., Iyer, M. K., Jiang, X., Borkin, D., Escara-Wilke, J. F., et al. (2015) · Nature Medicine · doi:10.1038/nm.3830 · Cited by 219
Self-citationThe metabolic co-regulator PGC1α suppresses prostate cancer metastasis
Torrano, V., Valcárcel-Jiménez, L., Cortázar, A. R., Liu, X., Urosevic, J., Castillo-Martín, M., Fernández‐Ruiz, S., Morciano, G., Caro‐Maldonado, A., Guiu, M., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3357 · Cited by 220
Huang, Q., Whitington, T., Gao, P. H., Lindberg, J., Yang, Y., Sun, J., Väisänen, M., Szulkin, R., Annala, M., Yan, J., et al. (2014) · Nature Genetics · doi:10.1038/ng.2862 · Cited by 209
Blattner, M., Liu, D., Robinson, B. D., Huang, D., Poliakov, A., Gao, D., Nataraj, S., Deonarine, L. D., Augello, M. A., Sailer, V., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.004 · Cited by 204
Self-citationNADPH Oxidases: A Perspective on Reactive Oxygen Species Production in Tumor Biology
Meitzler, J. L., Antony, S., Wu, Y., Juhasz, A. N., Liu, H., Jiang, G., Lu, J., Roy, K., & Doroshow, J. H. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5603 · Cited by 213
Self-citationIntegrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome
You, S., Knudsen, B. S., Erho, N., Alshalalfa, M., Takhar, M. M., Ashab, H. A.-D., Davicioni, E., Karnes, R. J., Klein, E. A., Den, R. B., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0902 · Cited by 209
Prostate organogenesis: tissue induction, hormonal regulation and cell type specification
Toivanen, R., & Shen, M. M. (2017) · Development · doi:10.1242/dev.148270 · Cited by 224
Lipid metabolism in prostate cancer.
Wu, X., Daniels, G., Lee, P., & Monaco, M. E. (2014) · PubMed Central · Cited by 204
Prostate cancer, PI3K, PTEN and prognosis
Wise, H. M., Hermida, M. A., & Leslie, N. R. (2017) · Clinical Science · doi:10.1042/cs20160026 · Cited by 212
Zou, J. X., Duan, Z., Wang, J., Sokolov, A., Xu, J., Chen, C. Z., Li, J. J., & Chen, H.-W. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0459 · Cited by 202
Cancer: Evolution Within a Lifetime
Gerlinger, M., McGranahan, N., Dewhurst, S. M., Burrell, R. A., Tomlinson, I. P. M., & Swanton, C. (2014) · Annual Review of Genetics · doi:10.1146/annurev-genet-120213-092314 · Cited by 210
Shah, N., Wang, P., Wongvipat, J., Karthaus, W. R., Abida, W. M., Armenia, J., Rockowitz, S., Drier, Y., Bernstein, B., Long, H. W., et al. (2017) · eLife · doi:10.7554/elife.27861 · Cited by 207
Wang, J., Zou, J. X., Xue, X., Cai, D., Zhang, Y., Duan, Z., Xiang, Q., Yang, J. C., Louie, M. C., Borowsky, A. D., et al. (2016) · Nature Medicine · doi:10.1038/nm.4070 · Cited by 204
Nassar, Z. D., Mah, C. Y., Dehairs, J., Burvenich, I. J. G., Irani, S., Centenera, M. M., Helm, M., Shrestha, R. K., Moldovan, M. V., Don, A. S., et al. (2020) · eLife · doi:10.7554/elife.54166 · Cited by 199
Ren, S., Wei, G., Liu, D., Wang, L., Hou, Y., Zhu, S., Peng, L., Zhang, Q., Cheng, Y., Su, H. L., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.08.027 · Cited by 198
Pettitt, S. J., Frankum, J. R., Punta, M., Lise, S., Alexander, J. J., Chen, Y., Yap, T. A., Haider, S. A., Tutt, A. N. J., & Lord, C. J. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1485 · Cited by 200
Harouaka, R. A., Kang, Z., Zheng, S.-Y., & Cao, L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.004 · Cited by 200
Ferraldeschi, R., Welti, J. C., Luo, J., Attard, G., & Bono, J. S. D. (2014) · Oncogene · doi:10.1038/onc.2014.115 · Cited by 199
Molecular and cellular heterogeneity: the hallmark of glioblastoma
Aum, D. J., Kim, D. H., Beaumont, T., Leuthardt, E. C., Dunn, G. P., & Kim, A. H. (2014) · Neurosurgical FOCUS · doi:10.3171/2014.9.focus14521 · Cited by 200
Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence
Coutinho, I., Day, T. K., Tilley, W. D., & Selth, L. A. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0422 · Cited by 197
Neuroendocrine differentiation of prostate cancer leads to PSMA suppression
Bakht, M. K., Derecichei, I., Li, Y., Ferraiuolo, R., Dunning, M., Oh, S. W., Hussein, A. A., Youn, H., Stringer, K. F., Jeong, C. W., et al. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0226 · Cited by 194
Liu, Y., Chen, J., Sethi, A., Li, Q. K., Chen, L., Collins, B. C., Gillet, L. C. J., Wollscheid, B., Zhang, H., & Aebersold, R. H. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.038273 · Cited by 187
A prospective investigation of PTEN loss and ERG expression in lethal prostate cancer
Ahearn, T. U., Pettersson, A., Ebot, E. M., Gerke, T., Graff, R. E., Morais, C. L., Hicks, J. L., Wilson, K. M., Rider, J. R., Sesso, H. D., et al. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv346 · Cited by 186
LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer
Wang, D., Ding, L., Wang, L., Zhao, Y., Sun, Z., Karnes, R. J., Zhang, J., & Huang, H. (2015) · Oncotarget · doi:10.18632/oncotarget.5728 · Cited by 189
Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program
Jin, H., Zhao, J. C., Wu, L., Kim, J., & Yu, J. (2014) · Nature Communications · doi:10.1038/ncomms4972 · Cited by 191
Pioneer of prostate cancer: past, present and the future of FOXA1
Teng, M., Zhou, S., Cai, C., Lupien, M., & He, H. H. (2020) · Protein & Cell · doi:10.1007/s13238-020-00786-8 · Cited by 180
Stopsack, K. H., Nandakumar, S., Wibmer, A. G., Haywood, S., Weg, E. S., Barnett, E. S., Kim, C. J., Carbone, E. A., Vasselman, S. E., Nguyen, B., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0168 · Cited by 177
Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer
Kang, J., Manna, F. L., Bonollo, F., Sampson, N., Alberts, I., Mingels, C., Afshar‐Oromieh, A., Thalmann, G. N., & Karkampouna, S. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.01.015 · Cited by 185
Wang, Q., Tiffen, J. C., Bailey, C. G., Lehman, M., Ritchie, W., Fazli, L., Metierre, C., Feng, Y., Li, E., Gleave, M. E., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt241 · Cited by 175
Baena, E., Shao, Z., Linn, D. E., Glass, K., Hamblen, M. J., Fujiwara, Y., Kim, J., Nguyen, M., Zhang, X., Godinho, F. J., et al. (2013) · Genes & Development · doi:10.1101/gad.211011.112 · Cited by 181
Voltage-gated calcium channels: Novel targets for cancer therapy
Phan, N. N., Wang, C., Chen, C., Sun, Z., Lai, M., & Lin, Y. (2017) · Oncology Letters · doi:10.3892/ol.2017.6457 · Cited by 174
Henzler, C., Li, Y., Yang, R., McBride, T., Ho, Y., Sprenger, C., Liu, G., Coleman, I., Lakely, B., Li, R., et al. (2016) · Nature Communications · doi:10.1038/ncomms13668 · Cited by 173
Maintaining and reprogramming genomic androgen receptor activity in prostate cancer
Mills, I. G. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3678 · Cited by 172
Latonen, L., Afyounian, E., Jylhä, A., Nättinen, J. E., Aapola, U., Annala, M., Kivinummi, K. K., Tammela, T. L. J., Beuerman, R. W., Uusitalo, H. M. T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03573-6 · Cited by 181
Targeting androgen receptor phase separation to overcome antiandrogen resistance
Xie, J., He, H., Kong, W., Li, Z., Gao, Z., Xie, D., Sun, L., Fan, X., Jiang, X., Zheng, Q., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01151-y · Cited by 173
Targeting the Androgen Signaling Axis in Prostate Cancer
Dai, C. S., Dehm, S. M., & Sharifi, N. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00433 · Cited by 182
STAT3 regulated ARF expression suppresses prostate cancer metastasis
Pěnčík, J., Schlederer, M., Gruber, W., Unger, C., Walker, S. M., Chalaris, A., Marié, I. J., Hassler, M. R., Javaheri, T., Aksoy, O., et al. (2015) · Nature Communications · doi:10.1038/ncomms8736 · Cited by 172
Translating cancer genomes and transcriptomes for precision oncology
Roychowdhury, S., & Chinnaiyan, A. M. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21329 · Cited by 168
Self-citationFu, X., Jeselsohn, R. M., Pereira, R., Hollingsworth, E. F., Creighton, C. J., Li, F., Shea, M. J., Nardone, A., Angelis, C. D., Heiser, L. M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612835113 · Cited by 172
Self-citationDUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4
Jin, X., Yan, Y., Wang, D., Ding, D., Ma, T., Ye, Z., Jiménez, R. E., Wang, L., Wu, H., & Huang, H. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.06.036 · Cited by 169
Lysine Demethylase KDM6A in Differentiation, Development, and Cancer
Tran, N., Broun, A., & Ge, K. (2020) · Molecular and Cellular Biology · doi:10.1128/mcb.00341-20 · Cited by 170
CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion
Tien, J. F., Mazloomian, A., Cheng, S., Hughes, C. S., Chow, C. C. T., Canapi, L. T., Oloumi, A., Trigo‐Gonzalez, G., Bashashati, A., Xu, J., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx187 · Cited by 169
Wang, L., & Shilatifard, A. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.001 · Cited by 165
MLL3/MLL4/COMPASS Family on Epigenetic Regulation of Enhancer Function and Cancer
Sze, C. C., & Shilatifard, A. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026427 · Cited by 164
Komura, K., Jeong, S. H., Hinohara, K., Qu, F., Wang, X., Hiraki, M., Azuma, H., Lee, G. M., Kantoff, P. W., & Sweeney, C. J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600420113 · Cited by 163
Metadata
- Authors
- Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., Asangani, I. A., Ateeq, B., Chun, S. Y., Siddiqui, J., Sam, L., Anstett, M., Mehra, R., Prensner, J. R., Palanisamy, N., Ryslik, G. A., Vandin, F., Raphael, B. J., Kunju, L. P., Rhodes, D. R., Pienta, K. J., Chinnaiyan, A. M., & Tomlins, S. A.
- Affiliations
- University of Michigan (US)
- Howard Hughes Medical Institute (US)
- Yale University (US)
- Brown University (US)
- Corresponding author
- Pienta, Kenneth J.
- Chinnaiyan, Arul M.
- ORCID
- Grasso, Catherine S.
- Robinson, Dan R.
- Cao, Xuhong
- Dhanasekaran, Saravana M.
- Khan, Amjad P.
- Jing, Xiaojun
- Brenner, J. Chad
- Asangani, Irfan A.
- Ateeq, Bushra
- Siddiqui, Javed
- Mehra, Rohit
- Prensner, John R.
- Palanisamy, Nallasivam
- Ryslik, Gregory A.
- Vandin, Fabio
- Raphael, Benjamin J.
- Kunju, Lakshmi P.
- Rhodes, Daniel R.
- Pienta, Kenneth J.
- Chinnaiyan, Arul M.
- Tomlins, Scott A.
- Venue
- Nature
- Published
- 2012-05-20
- Volume
- 487
- Issue
- 7406
- Pages
- 239-243
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3396711
- OpenAlex
- W2051025382
- Cited by
- 2,517
- References
- 23
- Citations by year
- 2026: 75 · 2025: 128 · 2024: 136 · 2023: 181 · 2022: 178 · 2021: 199 · 2020: 233 · 2019: 193 · 2018: 205 · 2017: 195 · 2016: 194 · 2015: 212 · 2014: 177 · 2013: 169 · 2012: 33
- FWCI
- 152.73
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (5r01ca013287-14)
- National Cancer Institute (P50-CA-69568, R01CA132874, U01CA111275, R01CA13287, P50CA069568, T32CA140044, P30CA046592, T32CA009676, U01CA113913)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- castration-resistant prostate cancer, metastatic prostate cancer, somatic mutations, copy number alterations, chromatin modifiers, androgen receptor, FOXA1, KMT2D, TMPRSS2-ERG fusion, PTEN loss, androgen receptor amplification, chromosomal rearrangements
- MeSH terms
- Cells, Cultured, Humans, Male, Molecular Sequence Data, Mutation, Orchiectomy, Prostatic Neoplasms, Receptors, Androgen, Signal Transduction, Sequence Alignment, Cell Proliferation, Hepatocyte Nuclear Factor 3-alpha
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
